DrugId:  1
1. Name:  Pyroxamide
2. Groups:  Investigational
3. Description:  Pyroxamide has been used in trials studying the treatment of Leukemia, Lymphoma, Small Intestine Cancer, Precancerous Condition, and Myelodysplastic Syndromes, among others.
4. Indication:  Not Available
DrugId:  2
1. Name:  Exisulind
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in adenomatous polyposis coli, lung cancer, prostate cancer, colon polyps, Barrett's esophagus disease, and pediatric indications.
DrugId:  3
1. Name:  Amolimogene
2. Groups:  Investigational
3. Description:  Amolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV). Amolimogene was biologically engineered as a targeted therapy for the treatment of cervical dysplasia.
4. Indication:  Intended for the treatment of cervical dysplasia associated with the human papillomavirus (HPV).
DrugId:  4
1. Name:  Masoprocol
2. Groups:  Approved, Investigational
3. Description:  A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils. [PubChem]
4. Indication:  Used for the treatment of actinic keratoses (precancerous skin growths that can become malignant if left untreated).
DrugId:  5
1. Name:  Ligandrol
2. Groups:  Investigational
3. Description:  Ligandrol is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis.
4. Indication:  Not Available
DrugId:  6
1. Name:  MVA3000
2. Groups:  Investigational
3. Description:  MVA3000 is an attenuated smallpox vaccine that is being developed for use in people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of the immune system or skin conditions such as eczema.
4. Indication:  Investigated for use/treatment in viral infection.
DrugId:  7
1. Name:  Fluorine F-18
2. Groups:  Investigational
3. Description:  Fluorine-18 is under investigation in clinical trial NCT00870974 (A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions).
4. Indication:  Not Available
DrugId:  8
1. Name:  ROX-888
2. Groups:  Investigational
3. Description:  ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain, including post-operative pain. 
4. Indication:  Investigated for use/treatment in pain (acute or chronic).
DrugId:  9
1. Name:  RAD-140
2. Groups:  Experimental, Investigational
3. Description:  RAD140 is an investigational selective androgen receptor modulator (SARM) for the treatment of conditions such as muscle wasting and breast cancer.
4. Indication:  Not Available
DrugId:  10
1. Name:  T487
2. Groups:  Investigational
3. Description:  T487 is a small molecule chemokine receptor antagonist to correct or modify immune system responses. It binds selectively and potently to CXCR3. The formulation is administered orally and has anti-inflammatory effects in conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis.
4. Indication:  Investigated for use/treatment in inflammatory disorderssuch as rheumatoid arthritis, inflammatory bowel disease and psoriasis.
DrugId:  11
1. Name:  ATG002
2. Groups:  Investigational
3. Description:  ATG002 is a completely new approach to treating chronic wounds such as diabetic foot ulcers, which is based upon stimulation of angiogenesis in the wound bed to help drive the wound-healing process. Unlike protein-derived growth factors, ATG002 is a small molecule that, applied topically, effectively penetrates through the wound and into surrounding tissues.
4. Indication:  Investigated for use/treatment in diabetic foot ulcers and wounds.
DrugId:  12
1. Name:  Metaxalone
2. Groups:  Approved
3. Description:  Metaxalone (marketed by King Pharmaceuticals under the brand name Skelaxin®) is a muscle relaxant used to relax muscles and relieve pain caused by strains, sprains, and other musculoskeletal conditions. Its exact mechanism of action is not known, but it may be due to general central nervous system depression. It is considered to be a moderately strong muscle relaxant, with relatively low incidence of side effects. Skelaxin comes in an 800 mg scored tablet. It previously came in both 400 mg and 800 mg tablets. The 400 mg tablet has been discontinued. Possible side effects include nausea, vomiting, drowsiness and CNS side effects such as dizziness, headache, and irritability.
4. Indication:  For the treatment of painful peripheral musculoskeletal conditions and spasticity from upper motor neuron syndromes.
DrugId:  13
1. Name:  Nicaraven
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in cerebrovascular disease (unspecified).
DrugId:  14
1. Name:  MPI-674
2. Groups:  Investigational
3. Description:  MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile. AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen. It is developed for the treatment of several serious women’s health conditions including endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding (AUB).
4. Indication:  Investigated for use/treatment in menstrual disorders.
DrugId:  15
1. Name:  PR-104
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.
DrugId:  16
1. Name:  Dextran 75
2. Groups:  Approved
3. Description:  Dextran 75 is a complex branched glucan with an average molecular weight 75000 Daltons. It is produced from certain bacteria that with α-1,6 glycosidic linkages between glucose molecules and α-1,3 linkages between branches. Dextrans are used therapeutically as plasma volume expanders in hypovolemia and antithrombin agents to reduce blood viscosity. When labelled with technetium Tc99m, dextran 75 is intravenously administered as an imaging agent to detect and diagnose conditions in the vascular compartment such as pericardial effusion or ventricular aneurysm.
4. Indication:  Not Available
DrugId:  17
1. Name:  J147
2. Groups:  Experimental
3. Description:  J147 is an experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of accelerated aging. [1, 2, 3] It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging that impacts many pathways implicated in the pathogenesis of diabetic neuropathy. [5]
4. Indication:  Not Available
DrugId:  18
1. Name:  Isoflurophate
2. Groups:  Approved, Investigational, Withdrawn
3. Description:  An irreversible cholinesterase inhibitor with actions similar to those of echothiophate. It is a powerful miotic used mainly in the treatment of glaucoma. Its vapor is highly toxic and it is recommended that only solutions in arachis oil be used therapeutically. (From Martindale, The Extra Pharmacopoeia, 29th ed, p1330)
4. Indication:  For use in the eye to treat certain types of glaucoma and other eye conditions, such as accommodative esotropia.
DrugId:  19
1. Name:  Alverine
2. Groups:  Approved, Investigational
3. Description:  Alverine is a smooth muscle relaxant. Smooth muscle is a type of muscle that is not under voluntary control; it is the muscle present in places such as the gut and uterus. Alverine acts directly on the muscle in the gut, causing it to relax. This prevents the muscle spasms which occur in the gut in conditions such as irritable bowel syndrome and diverticular disease. It is used to relieve cramps or spasms of the stomach and intestines. It is also useful in treating irritable bowel syndrome (IBS) and similar conditions. It can also be used to help relieve period pain. Alverine is formulated as the citrate salt (5982-87-6).
4. Indication:  Used to relieve cramps or spasms of the stomach and intestines. It is also useful in treating irritable bowel syndrome (IBS) and similar conditions. It can also be used to help relieve period pain. Alverine citrate is also under investigation to increase the cytotoxic effects of the proteasome inhibitor MG132 on breast cancer cells. 
DrugId:  20
1. Name:  AC3056
2. Groups:  Investigational
3. Description:  AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals. It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials.
4. Indication:  For the treatment of atherosclerosis and other conditions related to the obstruction of blood vessels.
DrugId:  21
1. Name:  XL019
2. Groups:  Investigational
3. Description:  XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.
4. Indication:  For the treatment of various forms of cancer.
DrugId:  22
1. Name:  DAS-431 IV
2. Groups:  Investigational
3. Description:  DAS-431 IV is a dopamine D1 receptor agonist developed by DrugAbuse Sciences for the treatment of Addictions, Schizophrenia, Schizoaffective Disorders, Dementia, Parkinson's Disease, Strokes etc. 
4. Indication:  Investigated for use/treatment in addictions, dementia, parkinson's disease, schizophrenia and schizoaffective disorders, and strokes.
DrugId:  23
1. Name:  Bromelains
2. Groups:  Approved, Experimental
3. Description:  Bromelain is a protease enzyme derived from the stems of pineapples that is composed of a mixture of different thiol endopeptidases and other components like phosphatase, glucosidase, peroxidase, cellulase, escharase, and several protease inhibitors [2]. It works by selectively inhibiting the biosynthesis of proinflammatory prostaglandins [1] and also has analgesic properties, as well as anticancerous and pro-apoptotic effects. Bromelain holds potential therapeutic effect as a treatment of conditions including angina pectoris, bronchitis, sinusitis, surgical trauma, and osteoarthritis. It is considered as a safe food supplement.
4. Indication:  Not Available
DrugId:  24
1. Name:  Pancrelipase lipase
2. Groups:  Approved
3. Description:  is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiencydue to cystic fibrosis or other conditions.
4. Indication:  Pancrelipase is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. 
DrugId:  25
1. Name:  KC706
2. Groups:  Investigational
3. Description:  KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. KC706 holds potential to treat inflammatory conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and cardiovascular disease.
4. Indication:  Investigated for use/treatment in cardiovascular disorders, inflammatory bowel disease, inflammatory disorders (unspecified), psoriasis and psoriatic disorders, and rheumatoid arthritis.
